Shareholder value will be created with increased market penetration through the Company's partnership channels, with the low cost of capital from its licensees, and by diversifying revenue exposure ...
The higher net revenue in the third quarter of 2024 was due to increased sales of soft tissue repair products (CellerateRX ® Surgical Activated Collagen ®, BIASURGE ®, FORTIFY TRG ® Tissue Repair ...